Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GW873140 + lopinavir + ritonavir
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GW873140 + lopinavir + ritonavir is a triple antiretroviral drug regimen investigated for the treatment of HIV infection. GW873140 (also known as aplaviroc) is a small molecule antagonist of CC chemokine receptor 5 (CCR5), blocking HIV entry by inhibiting virus interaction with the host cell receptor[2]. Lopinavir and ritonavir are both HIV-1 protease inhibitors; ritonavir 'boosts' lopinavir levels by inhibiting its metabolism[1][5][7]. This combination acts via two mechanisms: blocking viral entry (CCR5 antagonism) and inhibiting viral protease, disrupting HIV replication. GW873140 development was discontinued because of hepatotoxicity[6], but drug–drug interaction studies showed that combination with lopinavir/ritonavir boosts GW873140 plasma levels and was well tolerated short-term[3]. Lopinavir/ritonavir (marketed as Kaletra) is approved as part of combination therapy for HIV/AIDS[1][5][7].
- Brand names
- Kaletra
- Other names
- aplaviroc + lopinavir + ritonavirlopinavir/ritonavir
02
Targets
CCR5 (C-C chemokine receptor type 5)PR (Progesterone receptor)
Beyond the preview
Go deeper on GW873140 + lopinavir + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GW873140 + lopinavir + ritonavir.